• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    9/16/22 8:20:19 AM ET
    $ADXN
    $ALHC
    $BEAT
    $CMRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $ADXN alert in real time by email

     

    Gainers

    • Quotient (NASDAQ:QTNT) shares increased by 15.7% to $0.24 during Friday's pre-market session. The company's market cap stands at $32.5 million.
    • Tyme Technologies (NASDAQ:TYME) stock moved upwards by 13.21% to $0.33. The market value of their outstanding shares is at $56.0 million.
    • Landos Biopharma (NASDAQ:LABP) shares increased by 10.47% to $1.16. The company's market cap stands at $46.6 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) stock moved upwards by 9.06% to $1.34. The company's market cap stands at $41.4 million.
    • Addex Therapeutics (NASDAQ:ADXN) shares rose 8.84% to $1.04. The market value of their outstanding shares is at $8.5 million.
    • 9 Meters Biopharma (NASDAQ:NMTR) shares moved upwards by 8.75% to $0.25. The company's market cap stands at $64.9 million.

    Losers

    • Comera Life Sciences (NASDAQ:CMRA) stock decreased by 18.5% to $2.91 during Friday's pre-market session. The company's market cap stands at $55.5 million.
    • Alignment Healthcare (NASDAQ:ALHC) stock fell 12.5% to $14.0. The company's market cap stands at $2.6 billion.
    • NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock declined by 10.56% to $22.2. The company's market cap stands at $19.7 million.
    • Ontrak (NASDAQ:OTRKP) shares declined by 10.24% to $1.7.
    • BioTelemetry (NASDAQ:BEAT) shares fell 9.06% to $2.11. The company's market cap stands at $72.3 million.
    • Tenax Therapeutics (NASDAQ:TENX) shares fell 8.62% to $0.24. The company's market cap stands at $5.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADXN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXN
    $ALHC
    $BEAT
    $CMRA

    CompanyDatePrice TargetRatingAnalyst
    Heartbeam Inc.
    $BEAT
    12/11/2025$8.00Speculative Buy → Buy
    The Benchmark Company
    Heartbeam Inc.
    $BEAT
    12/8/2025$2.50Buy
    H.C. Wainwright
    Alignment Healthcare Inc.
    $ALHC
    11/24/2025$20.00Neutral → Overweight
    Analyst
    Heartbeam Inc.
    $BEAT
    10/31/2025$4.00Buy
    Roth Capital
    Alignment Healthcare Inc.
    $ALHC
    10/14/2025$21.00Buy
    Goldman
    Tenax Therapeutics Inc.
    $TENX
    9/8/2025$20.00Overweight
    Piper Sandler
    Alignment Healthcare Inc.
    $ALHC
    8/25/2025$21.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Alignment Healthcare Inc.
    $ALHC
    7/31/2025$13.00Underweight → Equal Weight
    Barclays
    More analyst ratings

    $ADXN
    $ALHC
    $BEAT
    $CMRA
    SEC Filings

    View All

    SEC Form 10-K filed by Alignment Healthcare Inc.

    10-K - Alignment Healthcare, Inc. (0001832466) (Filer)

    2/26/26 9:18:05 PM ET
    $ALHC
    Medical Specialities
    Health Care

    Alignment Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Alignment Healthcare, Inc. (0001832466) (Filer)

    2/26/26 4:01:29 PM ET
    $ALHC
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Alignment Healthcare Inc.

    SCHEDULE 13G/A - Alignment Healthcare, Inc. (0001832466) (Subject)

    2/17/26 4:34:37 PM ET
    $ALHC
    Medical Specialities
    Health Care

    $ADXN
    $ALHC
    $BEAT
    $CMRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics

    Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted gross profit and adjusted EBITDARaises health plan membership guidance by 2,000 at the midpoint and introduces 2026 revenue guidance of $5.14 billion to $5.19 billion, representing 30%-31% growth year-over-year, and adjusted EBITDA of $133 million to $163 millionEarns recognition on the 2026 Fortune World's Most Admired Companies™ list, underscoring the company's innovative approach to senior health care ORANGE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ:ALHC),

    2/26/26 4:01:00 PM ET
    $ALHC
    Medical Specialities
    Health Care

    Alignment Healthcare to Present at the Leerink Partners Global Healthcare Conference

    ORANGE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ:ALHC), today announced that it will present at the Leerink Partners Global Healthcare Conference in Miami, Florida, on Tuesday, March 10, at 3:40 p.m. EST. A webcast and replay of the presentation will be available on Alignment's investor relations website at https://ir.alignmenthealth.com/. About Alignment HealthcareAlignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ:ALHC), Alignment Health's mission-focused team makes high-quality, low-cost care a reality for its Medicare Adv

    2/23/26 8:00:00 AM ET
    $ALHC
    Medical Specialities
    Health Care

    Alignment Healthcare to Announce Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call Thursday, Feb. 26, 2026

    ORANGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ:ALHC), will release its fourth quarter and full-year 2025 financial results on Thursday, Feb. 26, 2026, after market close. Following the release, the company will host a conference call to review its financial results at 5 p.m. EST. Conference Call DetailsA live audio webcast will be available online at https://ir.alignmenthealth.com/. At the start of the conference call, participants may access the webcast at the following link: https://edge.media-server.com/mmc/p/kd529mia A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same we

    2/5/26 8:00:00 AM ET
    $ALHC
    Medical Specialities
    Health Care

    $ADXN
    $ALHC
    $BEAT
    $CMRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rich Stuart bought $50,792 worth of shares (5,000 units at $10.16), increasing direct ownership by 90% to 5,266 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/10/25 6:48:57 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rich Stuart bought $45,622 worth of shares (5,000 units at $9.12), increasing direct ownership by 940% to 2,766 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/5/25 5:46:32 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Giordano Christopher Thomas bought $20,000 worth of shares (2,605 units at $7.68) (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    11/20/25 6:38:51 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $ALHC
    $BEAT
    $CMRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HeartBeam upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded HeartBeam from Speculative Buy to Buy and set a new price target of $8.00

    12/11/25 8:45:10 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on HeartBeam with a new price target

    H.C. Wainwright initiated coverage of HeartBeam with a rating of Buy and set a new price target of $2.50

    12/8/25 8:34:44 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Alignment Healthcare upgraded by Analyst with a new price target

    Analyst upgraded Alignment Healthcare from Neutral to Overweight and set a new price target of $20.00

    11/24/25 8:06:33 AM ET
    $ALHC
    Medical Specialities
    Health Care

    $ADXN
    $ALHC
    $BEAT
    $CMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Digital Officer Mansour Adnan R. was granted 23,441 shares (SEC Form 4)

    4 - Alignment Healthcare, Inc. (0001832466) (Issuer)

    2/23/26 5:14:30 PM ET
    $ALHC
    Medical Specialities
    Health Care

    President Maroney Dawn Christine sold $618,990 worth of shares (30,000 units at $20.63), decreasing direct ownership by 3% to 997,015 units (SEC Form 4)

    4 - Alignment Healthcare, Inc. (0001832466) (Issuer)

    2/17/26 7:53:27 PM ET
    $ALHC
    Medical Specialities
    Health Care

    Chief Human Resources Officer Wagner Andreas P. sold $455,212 worth of shares (22,238 units at $20.47), decreasing direct ownership by 12% to 169,805 units (SEC Form 4)

    4 - Alignment Healthcare, Inc. (0001832466) (Issuer)

    2/10/26 9:51:27 PM ET
    $ALHC
    Medical Specialities
    Health Care

    $ADXN
    $ALHC
    $BEAT
    $CMRA
    Leadership Updates

    Live Leadership Updates

    View All

    HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

    Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate

    1/22/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Alignment Health Appoints Adnan Mansour as Chief Digital Officer to Accelerate AI-Driven Growth and Technology Leadership

    ORANGE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Alignment Health, an award-winning Medicare Advantage (MA) company, today announced the appointment of Adnan Mansour as chief digital officer, an executive leadership role that unifies the company's technology and information functions to drive scalable growth and continued innovation. Mansour, formerly senior vice president and chief information officer at Optum Insight – the data, analytics and managed services division of UnitedHealth Group – brings decades of experience leading global IT and engineering teams and embedding artificial intelligence (AI) into complex health care systems. Effective Jan. 19, Mansour reports to Alignment Hea

    1/20/26 8:00:00 AM ET
    $ALHC
    Medical Specialities
    Health Care

    Addex Appoints Bank of New York Mellon as Depositary Bank

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment the Bank of New-York Mellon (BNY) as its new ADS depositary agent. This change is expected to become effective on October 6, 2025.  The appointment of BNY has no impact on the fees paid by ADS holders. At the effective date, no action will be required by the ADS holders. About Addex Therapeutics Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a

    9/23/25 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $ALHC
    $BEAT
    $CMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tenax Therapeutics Inc.

    SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

    11/14/24 7:14:21 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alignment Healthcare Inc.

    SC 13G/A - Alignment Healthcare, Inc. (0001832466) (Subject)

    11/14/24 5:57:27 PM ET
    $ALHC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by NeuroBo Pharmaceuticals Inc.

    SC 13G - NeuroBo Pharmaceuticals, Inc. (0001638287) (Subject)

    11/14/24 3:34:00 PM ET
    $NRBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $ALHC
    $BEAT
    $CMRA
    Financials

    Live finance-specific insights

    View All

    Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics

    Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted gross profit and adjusted EBITDARaises health plan membership guidance by 2,000 at the midpoint and introduces 2026 revenue guidance of $5.14 billion to $5.19 billion, representing 30%-31% growth year-over-year, and adjusted EBITDA of $133 million to $163 millionEarns recognition on the 2026 Fortune World's Most Admired Companies™ list, underscoring the company's innovative approach to senior health care ORANGE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ:ALHC),

    2/26/26 4:01:00 PM ET
    $ALHC
    Medical Specialities
    Health Care

    Alignment Healthcare to Announce Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call Thursday, Feb. 26, 2026

    ORANGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ:ALHC), will release its fourth quarter and full-year 2025 financial results on Thursday, Feb. 26, 2026, after market close. Following the release, the company will host a conference call to review its financial results at 5 p.m. EST. Conference Call DetailsA live audio webcast will be available online at https://ir.alignmenthealth.com/. At the start of the conference call, participants may access the webcast at the following link: https://edge.media-server.com/mmc/p/kd529mia A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same we

    2/5/26 8:00:00 AM ET
    $ALHC
    Medical Specialities
    Health Care

    Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a corporate update. "We continue to make great progress with our GABAB positive allosteric modulator (PAM) candidate in chronic cough following demonstration of robust anti-tussive activity in multiple chronic cough preclinical models earlier in the year as well as advancing dipraglurant for post-stro

    12/4/25 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care